4π noncoplanar stereotactic body radiation therapy for head-and-neck cancer: Potential to improve tumor control and late toxicity

Jean Claude M Rwigema, Dan Nguyen, Dwight E. Heron, Allen M. Chen, Percy Lee, Pin Chieh Wang, John A. Vargo, Daniel A. Low, M. Saiful Huq, Stephen Tenn, Michael L. Steinberg, Patrick Kupelian, Ke Sheng

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Purpose: To evaluate the potential benefit of 4π radiation therapy in recurrent, locally advanced, or metastatic head-and-neck cancer treated with stereotactic body radiation therapy (SBRT). Methods and Materials: Twenty-seven patients with 29 tumors who were treated using SBRT were included. In recurrent disease (n=26), SBRT was delivered with a median 44 Gy (range, 35-44 Gy) in 5 fractions. Three patients with sinonasal mucosal melanoma, metastatic breast cancer, and primary undifferentiated carcinoma received 35 Gy, 22.5 Gy, and 40 Gy in 5 fractions, respectively. Novel 4π treatment plans were created for each patient to meet the objective that 95% of the planning target volume was covered by 100% of the prescription dose. Doses to organs at risk (OARs) and 50% dose spillage volumes were compared against the delivered clinical SBRT plans. Local control (LC), late toxicity, tumor control probability (TCP), and normal tissue complication probability were determined. Results: Using 4π plans, mean/maximum doses to all OARs were reduced by 22% to 89%/10% to 86%. With 4π plans, the 50% dose spillage volume was decreased by 33%. Planning target volume prescription dose escalation by 10 Gy and 20 Gy were achieved while keeping doses to OARs significantly improved or unchanged from clinical plans, except for the carotid artery maximum dose at 20-Gy escalation. At a median follow-up of 10 months (range, 1-41 months), crude LC was 52%. The 2-year LC of 39.2% approximated the predicted mean TCP of 42.2%, which increased to 45.9% with 4p plans. For 10-Gy and 20-Gy dose escalation, 4p plans increased TCP from 80.1% and 88.1% to 85.5% and 91.4%, respectively. The 7.4% rate of grade >3 late toxicity was comparable to the predicted 5.6% mean normal tissue complication probability for OARs, which was significantly reduced by 4p planning at the prescribed and escalated doses. Conclusions: 4p plans may allow dose escalation with significant and consistent improvements in critical organ sparing, tumor control, and coverage.

Original languageEnglish (US)
Pages (from-to)401-409
Number of pages9
JournalInternational Journal of Radiation Oncology Biology Physics
Volume91
Issue number2
DOIs
StatePublished - 2015

Fingerprint

Organs at Risk
Head and Neck Neoplasms
toxicity
radiation therapy
Radiotherapy
tumors
cancer
dosage
organs
Neoplasms
Prescriptions
planning
Carotid Arteries
Melanoma
Breast Neoplasms
Carcinoma
arteries
breast
grade

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Cite this

4π noncoplanar stereotactic body radiation therapy for head-and-neck cancer : Potential to improve tumor control and late toxicity. / Rwigema, Jean Claude M; Nguyen, Dan; Heron, Dwight E.; Chen, Allen M.; Lee, Percy; Wang, Pin Chieh; Vargo, John A.; Low, Daniel A.; Huq, M. Saiful; Tenn, Stephen; Steinberg, Michael L.; Kupelian, Patrick; Sheng, Ke.

In: International Journal of Radiation Oncology Biology Physics, Vol. 91, No. 2, 2015, p. 401-409.

Research output: Contribution to journalArticle

Rwigema, JCM, Nguyen, D, Heron, DE, Chen, AM, Lee, P, Wang, PC, Vargo, JA, Low, DA, Huq, MS, Tenn, S, Steinberg, ML, Kupelian, P & Sheng, K 2015, '4π noncoplanar stereotactic body radiation therapy for head-and-neck cancer: Potential to improve tumor control and late toxicity', International Journal of Radiation Oncology Biology Physics, vol. 91, no. 2, pp. 401-409. https://doi.org/10.1016/j.ijrobp.2014.09.043
Rwigema, Jean Claude M ; Nguyen, Dan ; Heron, Dwight E. ; Chen, Allen M. ; Lee, Percy ; Wang, Pin Chieh ; Vargo, John A. ; Low, Daniel A. ; Huq, M. Saiful ; Tenn, Stephen ; Steinberg, Michael L. ; Kupelian, Patrick ; Sheng, Ke. / 4π noncoplanar stereotactic body radiation therapy for head-and-neck cancer : Potential to improve tumor control and late toxicity. In: International Journal of Radiation Oncology Biology Physics. 2015 ; Vol. 91, No. 2. pp. 401-409.
@article{ea4dab156148469c93cad0a9345fd55e,
title = "4π noncoplanar stereotactic body radiation therapy for head-and-neck cancer: Potential to improve tumor control and late toxicity",
abstract = "Purpose: To evaluate the potential benefit of 4π radiation therapy in recurrent, locally advanced, or metastatic head-and-neck cancer treated with stereotactic body radiation therapy (SBRT). Methods and Materials: Twenty-seven patients with 29 tumors who were treated using SBRT were included. In recurrent disease (n=26), SBRT was delivered with a median 44 Gy (range, 35-44 Gy) in 5 fractions. Three patients with sinonasal mucosal melanoma, metastatic breast cancer, and primary undifferentiated carcinoma received 35 Gy, 22.5 Gy, and 40 Gy in 5 fractions, respectively. Novel 4π treatment plans were created for each patient to meet the objective that 95{\%} of the planning target volume was covered by 100{\%} of the prescription dose. Doses to organs at risk (OARs) and 50{\%} dose spillage volumes were compared against the delivered clinical SBRT plans. Local control (LC), late toxicity, tumor control probability (TCP), and normal tissue complication probability were determined. Results: Using 4π plans, mean/maximum doses to all OARs were reduced by 22{\%} to 89{\%}/10{\%} to 86{\%}. With 4π plans, the 50{\%} dose spillage volume was decreased by 33{\%}. Planning target volume prescription dose escalation by 10 Gy and 20 Gy were achieved while keeping doses to OARs significantly improved or unchanged from clinical plans, except for the carotid artery maximum dose at 20-Gy escalation. At a median follow-up of 10 months (range, 1-41 months), crude LC was 52{\%}. The 2-year LC of 39.2{\%} approximated the predicted mean TCP of 42.2{\%}, which increased to 45.9{\%} with 4p plans. For 10-Gy and 20-Gy dose escalation, 4p plans increased TCP from 80.1{\%} and 88.1{\%} to 85.5{\%} and 91.4{\%}, respectively. The 7.4{\%} rate of grade >3 late toxicity was comparable to the predicted 5.6{\%} mean normal tissue complication probability for OARs, which was significantly reduced by 4p planning at the prescribed and escalated doses. Conclusions: 4p plans may allow dose escalation with significant and consistent improvements in critical organ sparing, tumor control, and coverage.",
author = "Rwigema, {Jean Claude M} and Dan Nguyen and Heron, {Dwight E.} and Chen, {Allen M.} and Percy Lee and Wang, {Pin Chieh} and Vargo, {John A.} and Low, {Daniel A.} and Huq, {M. Saiful} and Stephen Tenn and Steinberg, {Michael L.} and Patrick Kupelian and Ke Sheng",
year = "2015",
doi = "10.1016/j.ijrobp.2014.09.043",
language = "English (US)",
volume = "91",
pages = "401--409",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - 4π noncoplanar stereotactic body radiation therapy for head-and-neck cancer

T2 - Potential to improve tumor control and late toxicity

AU - Rwigema, Jean Claude M

AU - Nguyen, Dan

AU - Heron, Dwight E.

AU - Chen, Allen M.

AU - Lee, Percy

AU - Wang, Pin Chieh

AU - Vargo, John A.

AU - Low, Daniel A.

AU - Huq, M. Saiful

AU - Tenn, Stephen

AU - Steinberg, Michael L.

AU - Kupelian, Patrick

AU - Sheng, Ke

PY - 2015

Y1 - 2015

N2 - Purpose: To evaluate the potential benefit of 4π radiation therapy in recurrent, locally advanced, or metastatic head-and-neck cancer treated with stereotactic body radiation therapy (SBRT). Methods and Materials: Twenty-seven patients with 29 tumors who were treated using SBRT were included. In recurrent disease (n=26), SBRT was delivered with a median 44 Gy (range, 35-44 Gy) in 5 fractions. Three patients with sinonasal mucosal melanoma, metastatic breast cancer, and primary undifferentiated carcinoma received 35 Gy, 22.5 Gy, and 40 Gy in 5 fractions, respectively. Novel 4π treatment plans were created for each patient to meet the objective that 95% of the planning target volume was covered by 100% of the prescription dose. Doses to organs at risk (OARs) and 50% dose spillage volumes were compared against the delivered clinical SBRT plans. Local control (LC), late toxicity, tumor control probability (TCP), and normal tissue complication probability were determined. Results: Using 4π plans, mean/maximum doses to all OARs were reduced by 22% to 89%/10% to 86%. With 4π plans, the 50% dose spillage volume was decreased by 33%. Planning target volume prescription dose escalation by 10 Gy and 20 Gy were achieved while keeping doses to OARs significantly improved or unchanged from clinical plans, except for the carotid artery maximum dose at 20-Gy escalation. At a median follow-up of 10 months (range, 1-41 months), crude LC was 52%. The 2-year LC of 39.2% approximated the predicted mean TCP of 42.2%, which increased to 45.9% with 4p plans. For 10-Gy and 20-Gy dose escalation, 4p plans increased TCP from 80.1% and 88.1% to 85.5% and 91.4%, respectively. The 7.4% rate of grade >3 late toxicity was comparable to the predicted 5.6% mean normal tissue complication probability for OARs, which was significantly reduced by 4p planning at the prescribed and escalated doses. Conclusions: 4p plans may allow dose escalation with significant and consistent improvements in critical organ sparing, tumor control, and coverage.

AB - Purpose: To evaluate the potential benefit of 4π radiation therapy in recurrent, locally advanced, or metastatic head-and-neck cancer treated with stereotactic body radiation therapy (SBRT). Methods and Materials: Twenty-seven patients with 29 tumors who were treated using SBRT were included. In recurrent disease (n=26), SBRT was delivered with a median 44 Gy (range, 35-44 Gy) in 5 fractions. Three patients with sinonasal mucosal melanoma, metastatic breast cancer, and primary undifferentiated carcinoma received 35 Gy, 22.5 Gy, and 40 Gy in 5 fractions, respectively. Novel 4π treatment plans were created for each patient to meet the objective that 95% of the planning target volume was covered by 100% of the prescription dose. Doses to organs at risk (OARs) and 50% dose spillage volumes were compared against the delivered clinical SBRT plans. Local control (LC), late toxicity, tumor control probability (TCP), and normal tissue complication probability were determined. Results: Using 4π plans, mean/maximum doses to all OARs were reduced by 22% to 89%/10% to 86%. With 4π plans, the 50% dose spillage volume was decreased by 33%. Planning target volume prescription dose escalation by 10 Gy and 20 Gy were achieved while keeping doses to OARs significantly improved or unchanged from clinical plans, except for the carotid artery maximum dose at 20-Gy escalation. At a median follow-up of 10 months (range, 1-41 months), crude LC was 52%. The 2-year LC of 39.2% approximated the predicted mean TCP of 42.2%, which increased to 45.9% with 4p plans. For 10-Gy and 20-Gy dose escalation, 4p plans increased TCP from 80.1% and 88.1% to 85.5% and 91.4%, respectively. The 7.4% rate of grade >3 late toxicity was comparable to the predicted 5.6% mean normal tissue complication probability for OARs, which was significantly reduced by 4p planning at the prescribed and escalated doses. Conclusions: 4p plans may allow dose escalation with significant and consistent improvements in critical organ sparing, tumor control, and coverage.

UR - http://www.scopus.com/inward/record.url?scp=84922457790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922457790&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2014.09.043

DO - 10.1016/j.ijrobp.2014.09.043

M3 - Article

C2 - 25482301

AN - SCOPUS:84922457790

VL - 91

SP - 401

EP - 409

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 2

ER -